Trial Profile
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 05 Nov 2010 New trial record.